Literature DB >> 21788982

Spondyloarthropathies: management of AS-new guidelines in the spotlight.

Atul A Deodhar.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21788982     DOI： 10.1038/nrrheum.2011.111

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.

Authors:  M Dougados; N Betteridge; G R Burmester; L Euller-Ziegler; F Guillemin; J Hirvonen; J Lloyd; S Ozen; J A P Da Silva; P Emery; J R Kalden; T Kvien; M Matucci-Cerinic; J Smolen
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

2.  Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.

Authors:  Astrid Wanders; Désirée van der Heijde; Robert Landewé; Jéhan-Michel Béhier; Andrei Calin; Ignazio Olivieri; Henning Zeidler; Maxime Dougados
Journal:  Arthritis Rheum       Date:  2005-06

3.  A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.

Authors:  Walter P Maksymowych; Gian S Jhangri; Avril A Fitzgerald; Sharon LeClercq; Peter Chiu; Alex Yan; Kenneth J Skeith; Stephen L Aaron; Joanne Homik; Paul Davis; Dale Sholter; Anthony S Russell
Journal:  Arthritis Rheum       Date:  2002-03

4.  2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.

Authors:  Désirée van der Heijde; Joachim Sieper; Walter P Maksymowych; Maxime Dougados; Rubén Burgos-Vargas; Robert Landewé; Martin Rudwaleit; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

5.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

6.  Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.

Authors:  D van der Heijde; R Landewé; S Einstein; P Ory; D Vosse; L Ni; S-L Lin; W Tsuji; J C Davis
Journal:  Arthritis Rheum       Date:  2008-05

7.  One-year open-label trial of thalidomide in ankylosing spondylitis.

Authors:  Feng Huang; Jieruo Gu; Wei Zhao; Jian Zhu; Jianglin Zhang; David Tak Yan Yu
Journal:  Arthritis Rheum       Date:  2002-06-15

8.  Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

Authors:  Robert D Inman; John C Davis; Désirée van der Heijde; Laura Diekman; Joachim Sieper; Sung Il Kim; Michael Mack; John Han; Sudha Visvanathan; Zhenhua Xu; Benjamin Hsu; Anna Beutler; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2008-11

9.  ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.

Authors:  D van der Heijde; E Lie; T K Kvien; J Sieper; F Van den Bosch; J Listing; J Braun; R Landewé
Journal:  Ann Rheum Dis       Date:  2008-12-05       Impact factor: 19.103

10.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.